JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Apellis Pharmaceuticals Inc

Cerrado

SectorSanidad

28.6 1.89

Resumen

Variación precio

24h

Actual

Mínimo

28.02

Máximo

28.89

Métricas clave

By Trading Economics

Ingresos

50M

-42M

Ventas

12M

178M

Margen de beneficios

-23.615

Empleados

705

EBITDA

50M

-30M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+28.14% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.2B

3.6B

Apertura anterior

26.71

Cierre anterior

28.6

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

108 / 371 Clasificación en Healthcare

Apellis Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 oct 2025, 20:49 UTC

Ganancias

Correction to Thermo Fisher Article on Oct. 22

23 oct 2025, 23:51 UTC

Charlas de Mercado

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 oct 2025, 23:49 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 oct 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 oct 2025, 23:37 UTC

Charlas de Mercado

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 oct 2025, 22:58 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

23 oct 2025, 22:57 UTC

Charlas de Mercado

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 oct 2025, 22:49 UTC

Adquisiciones, fusiones, absorciones

How Trump Sparked a New Era of State Capitalism -2-

23 oct 2025, 22:49 UTC

Adquisiciones, fusiones, absorciones

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 oct 2025, 22:17 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 oct 2025, 21:41 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 oct 2025, 21:05 UTC

Ganancias

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 oct 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

23 oct 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

23 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

23 oct 2025, 20:35 UTC

Ganancias

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 oct 2025, 20:28 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 oct 2025, 20:15 UTC

Charlas de Mercado
Ganancias

Global Commodities Roundup: Market Talk

23 oct 2025, 20:10 UTC

Ganancias

Newmont Mining 3Q Adj EPS $1.71

23 oct 2025, 20:10 UTC

Ganancias

Newmont Mining 3Q Sales $5.52B

23 oct 2025, 20:10 UTC

Ganancias

Newmont Mining 3Q EPS $1.67

23 oct 2025, 20:09 UTC

Ganancias

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 oct 2025, 20:07 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

23 oct 2025, 20:07 UTC

Charlas de Mercado
Ganancias

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 oct 2025, 20:07 UTC

Ganancias

Blackstone Looks to IPOs for Investment Exits -- Update

23 oct 2025, 20:05 UTC

Ganancias

Intel 3Q Gross Margin 38.2% >INTC

23 oct 2025, 20:04 UTC

Ganancias

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 oct 2025, 20:04 UTC

Ganancias

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 oct 2025, 20:04 UTC

Ganancias

Intel: 4Q Guidance Excludes Altera >INTC

23 oct 2025, 20:04 UTC

Ganancias

Intel Sees 4Q Adj EPS 8c >INTC

Comparación entre iguales

Cambio de precio

Apellis Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

28.14% repunte

Estimación a 12 Meses

Media 36.06 USD  28.14%

Máximo 60 USD

Mínimo 18 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Apellis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

17 ratings

10

Comprar

6

Mantener

1

Vender

Sentimiento

By Acuity

108 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
help-icon Live chat